GLP-1 Nutrient Deficiency Protocol 2026: Protein, Vitamins, Minerals & Lab Monitoring

Disclosures: This article is educational and is not medical advice. Some links are affiliate links (The Wellness Company, referral code ONEDAYMD, and Amazon Associates); we may earn a commission at no extra cost to you. Affiliate relationships do not change the evidence we report. See the full medical disclaimer below.

GLP-1 Advisor SERIES Evidence Update

By Dr. Frank Yap, MD · Published September 29, 2026 · Updated October 3, 2026 · Evidence reviewed through early October 2026

Quick Answer: Do GLP-1 drugs cause nutrient deficiencies?

GLP-1 drugs such as semaglutide and tirzepatide are not known to drain vitamins directly. Nutrient risk rises mainly because appetite suppression, nausea, vomiting and rapid weight loss reduce intake of protein, vitamin D, iron, calcium and B vitamins. The best-supported approach is food first, protein plus resistance training, risk-based blood tests and targeted rather than blanket supplementation. Persistent vomiting, confusion or unsteady walking needs urgent medical care.

Core principle

The goal of GLP-1 nutrition is high-quality weight loss, not maximum appetite suppression: protect protein, muscle, bone, hydration and physical function while the scale drops.

Jump to a section

1. Quick answer
2. What changed in the October 2026 update
3. Why nutritional risk rises on GLP-1 therapy
4. What the 2026 evidence shows (with CEBM tiers)
5. Nutrient risk matrix
6. Protein and muscle preservation
7. Food-first protocol
8. Supplement strategy and safe limits
9. Which blood tests to consider
10. Managing nausea, vomiting, constipation, diarrhea
11. Thiamine and Wernicke encephalopathy
12. Risk tiers and warning signs
13. The 5-phase protection protocol
14. 10 common mistakes
15. Sample low-appetite day
16. Note for Malaysia and Singapore readers
17. AI personalization guide (Claude, ChatGPT, Gemini, Perplexity)
18. Tools and telehealth (affiliate)
19. Frequently asked questions
20. Medical references

What Changed in the October 2026 Update?

This page replaces broad supplement advice with a risk-based protocol and now grades each major claim by evidence level. The September 29 edition corrected the earlier blanket recommendations; this edition adds the items marked New.

↔ Swipe the table sideways to see all columns on mobile.

Topic	Earlier framing	Current framing (October 2026)
Mechanism	GLP-1 drugs “deplete” vitamins.	Risk is driven mainly by reduced intake, less dietary variety and GI intolerance. Direct depletion is not established.
Supplements	Routine high-dose thiamine, vitamin D, magnesium, iron.	Food first, then targeted replacement based on risk, symptoms and labs.
Lab schedule	Automatic tests every 3–6 months.	No universal interval; risk-based monitoring (2026 ADA Standards).
Protein	1.2–1.6 g/kg actual weight for everyone.	Proposed range only; body-weight denominator in obesity is uncertain; individualize.
Wernicke encephalopathy	Mostly theoretical.	Rare but serious signal supported by pharmacovigilance and case-based evidence. New: additional tirzepatide case report and a conference systematic review.
Deficiency statistics	Reported as GLP-1 effects.	New: clarified that the headline vitamin D figures come from a retrospective claims-data study of adults with type 2 diabetes, based on recorded diagnoses, not measured blood levels.
Multivitamin evidence	Not discussed.	New: a randomized trial of multivitamins in GLP-1 users is registered; no results yet.

Why Can GLP-1 Therapy Increase Nutritional Risk?

GLP-1 and other incretin-based therapies raise nutritional risk mainly by reducing how much, and how varied, a person eats. The pathway runs from lower appetite and earlier fullness, to smaller meals, to fewer calories and less variety, to lower intake of protein, micronutrients and fiber in susceptible people.

A joint scientific advisory reported energy-intake reductions of roughly 16%–39% in obesity-treatment studies. Reductions that large can make nutritional adequacy hard to reach, especially with very small meals or eliminated food groups.

Four risk pathways

• Less food: lower intake of protein, iron, calcium, magnesium and B vitamins.
• Less variety: reduced interest in meat, dairy or large meals narrows food groups even when remaining foods are healthy.
• GI intolerance: persistent nausea, vomiting or diarrhea reduces food and fluid intake and can worsen status quickly.
• Rapid weight loss: can reduce lean mass and may expose nutritional inadequacy that existed before treatment.

What Does the 2026 Evidence Show?

Observational data show nutrient abnormalities in GLP-1 users, led by vitamin D and iron, but they do not prove the drug directly causes them. The evidence below is graded using Oxford CEBM levels (1 = systematic review of RCTs, through 5 = mechanism-based reasoning or expert opinion).

Finding	Source / design	CEBM tier	What it does and does not show
Energy intake falls substantially on GLP-1 therapy (about 16%–39% in obesity studies).	Joint advisory (ACLM, ASN, OMA, TOS) 2025, summarizing trial-derived data	2 (RCT-derived, reported via advisory)	Strong support that intake falls; does not quantify deficiency.
Vitamin D deficiency was the most commonly recorded deficiency: 7.5% at 6 months and 13.6% at 12 months.	Retrospective claims analysis, 461,382 adults with type 2 diabetes newly prescribed GLP-1RAs; cited in the 2026 Clinical Obesity review	3–4 (retrospective cohort, diagnosis codes)	Records diagnoses, not systematic blood testing. Patients who saw a dietitian were more likely to have a recorded deficiency, which may reflect more testing rather than more harm.
Ferritin about 26%–30% lower than SGLT2-inhibitor comparators; many users below calcium and iron requirements.	2026 Clinical Obesity narrative review (six datasets, about 480,825 adults), as reported by the review	3 (observational comparison)	Association only; baseline status, diet quality and weight lost are confounders. We report these figures as stated by the review.
Wernicke encephalopathy reports: 15 cases identified across FDA reports, literature and one center.	Clinical Nutrition 2026 pharmacovigilance study and literature review	4 (case series / signal detection)	Signals a rare event; cannot give an incidence rate or prove causation. Most cases had GI symptoms, weight loss or malnutrition.
Six published semaglutide cases, all with prolonged GI symptoms and substantial weight loss before neurological decline.	Obesity 2026 systematic case review	4 (case series)	Consistent clinical pattern; very small numbers.
New: a tirzepatide case of Wernicke encephalopathy with optic neuropathy in a patient with multiple predisposing factors.	British Journal of Diabetes 2026 case report	4–5 (single case)	Illustrates the pattern; adds little to frequency estimates.
Protein 1.2–1.6 g/kg/day during active weight loss.	Joint advisory 2025	5 (expert consensus)	A proposed framework; the body-weight basis in obesity is not settled.
No universal micronutrient screening interval.	ADA Standards of Care 2026	5 (guideline statement)	Supports risk-based, individualized testing.
Routine multivitamin improves nutrient status in GLP-1 users.	No completed trial found; a randomized trial (NCT07234916) is registered	Evidence gap	Do not assume benefit or harm; individualize.

A 2026 consensus from European obesity and nutrition organizations (EASO, EFAD, ECPO) also stresses adequate protein, nutritional quality, early management of GI symptoms and progressive resistance exercise during incretin-based therapy.

Practical interpretation

• Assess food intake before and during therapy.
• Protect protein and keep dietary variety even when appetite is low.
• Treat persistent GI symptoms early.
• Identify higher-risk people; test selectively.
• Replace documented deficiencies rather than megadosing.
• Pair weight loss with resistance training.

GLP-1 Nutrient Risk Matrix

This matrix is a screening framework, not a diagnosis. Not everyone needs every test or supplement. Swipe sideways on mobile to see all columns.

Nutrient / factor	Why it matters on GLP-1 therapy	Food-first sources	Pay particular attention when	Typical assessment
Protein	Supports muscle, function and satiety; low intake can contribute to lean-mass loss.	Fish, eggs, poultry, Greek yogurt, dairy, tofu, tempeh, beans, lentils, nuts, seeds.	Very low appetite, small meals, rapid loss, older age, frailty, inactivity.	Dietary assessment; function or body-composition review when appropriate.
Vitamin D	Bone and muscle health; low status is common in obesity populations.	Fatty fish, fortified milk or plant drinks, eggs.	Prior deficiency, low intake, bone risk.	Serum 25-hydroxyvitamin D when indicated.
Iron	Hemoglobin, oxygen transport, energy metabolism.	Lean meat, seafood, legumes, tofu, fortified grains, leafy greens.	Heavy periods, vegetarian/vegan diet, prior deficiency, fatigue, blood loss.	CBC, ferritin, iron studies.
Vitamin B12	Red blood cells and nerve function.	Fish, meat, eggs, dairy, fortified plant foods.	Vegan diet, metformin, acid-suppressing drugs, neurologic symptoms.	Serum B12; methylmalonic acid if borderline.
Thiamine (B1)	Energy metabolism and brain function.	Whole grains, legumes, nuts, seeds, pork, fortified grains.	Persistent vomiting, severe restriction, rapid loss, heavy alcohol use, neurologic symptoms.	Clinical assessment is key; do not delay treatment if acute deficiency is strongly suspected.
Magnesium	Muscle, nerve and metabolic function.	Nuts, seeds, legumes, whole grains, leafy greens.	Very low intake, prolonged diarrhea, some medications or conditions.	Serum magnesium when appropriate.
Calcium	Bone and muscle function during substantial weight loss.	Dairy, fortified drinks, calcium-set tofu, canned fish with bones.	Low dairy intake, osteoporosis risk, older age.	Dietary assessment; serum calcium does not measure intake.
Zinc	Immune function, protein synthesis.	Seafood, meat, dairy, beans, nuts, seeds.	Highly restrictive diets, malabsorption.	Targeted testing only.
Folate / other B vitamins	Cell division, red blood cells.	Leafy greens, beans, lentils, citrus, fortified grains.	Restrictive diets, anemia, malabsorption.	By symptoms, diet and CBC.
Fiber	Bowel regularity, diet quality.	Vegetables, fruit, legumes, whole grains.	Constipation, very small meals.	Dietary assessment.
Fluids	Vomiting or diarrhea can cause dehydration and kidney injury.	Water, soups, water-rich foods.	Vomiting, diarrhea, fever, heat.	Clinical review; kidney function and electrolytes when indicated.

Protein: The Nutrient to Protect First

A proposed target during active weight loss is about 1.2–1.6 g of protein per kg per day, but it is a framework, not a mandatory dose. In people with obesity, actual body weight can substantially overestimate needs. Adjusted or reference body weight, or fat-free mass, may fit better; no single calculation is universally accepted. A registered dietitian can individualize the target, especially with obesity, older age, kidney disease, frailty or a very large calorie deficit.

Lean-mass loss during weight reduction varies with the size and speed of weight loss, protein intake, age, sex, baseline body composition and activity.

Making protein easier when appetite is low

• Eat protein first at each meal.
• Choose compact, protein-dense foods: Greek yogurt, cottage cheese, eggs, tofu, tempeh, fish.
• Spread protein across meals rather than loading one sitting.
• Use a protein shake when food alone keeps missing the individualized target.

Protein plus resistance training. Protein does not replace strength work. Progressive resistance exercise gives the mechanical signal to retain muscle, and the joint advisory specifically emphasizes it. The aim is preserved muscle function, not just a number on a body-composition scale. Adjust frequency and intensity for age, injuries and medical conditions.

The GLP-1 Food-First Nutrition Protocol

Step 1: Protect nutrient density

When appetite falls, every meal carries more weight. Anchor meals with protein, add vegetables and whole fruit (potassium, folate, vitamin C, fiber), include healthy fats (nuts, seeds, olive oil, avocado, fish) and whole-food carbohydrates (beans, lentils, oats, whole grains) as tolerated.

Step 2: Do not let appetite suppression become accidental starvation

“I am not hungry” does not mean “I do not need to eat.” The 2026 ADA Standards flag nutritional concern when intake falls below about 1,200 kcal/day for women or 1,800 kcal/day for men, while stressing individualized plans. These are risk markers, not personal calorie prescriptions.

Step 3: Keep fiber, adapted to symptoms

ADA 2026 nutrition guidance gives a general reference of at least 14 g fiber per 1,000 kcal. During active nausea, smaller amounts of bulky foods may be tolerated better. Aim for adequate fiber adapted to symptoms, not maximum fiber at all times.

Step 4: Hydration

Pay extra attention during dose escalation and any vomiting or diarrhea. Severe dehydration can cause dizziness, low blood pressure, electrolyte problems and acute kidney injury. People with heart failure or advanced kidney disease may have different fluid targets.

Step 5: Avoid unnecessary restriction

Strong appetite suppression combined with prolonged fasting, extreme carbohydrate restriction or rigid food rules makes adequate protein and micronutrients harder to reach. A lower-carbohydrate pattern can be compatible with GLP-1 treatment if it still includes enough vegetables, legumes, protein and variety. People using insulin or other glucose-lowering drugs need individualized medical advice before major diet changes.

Should You Take Supplements on a GLP-1?

Not automatically. Current guidance supports targeted supplementation when intake is inadequate, a deficiency is documented or risk factors are present. The 2026 ADA Standards say a multivitamin/mineral can be considered in selected circumstances such as very low energy intake, excluded nutrient-rich food groups, strict vegetarian diets, absorption problems, older age or excessive weight loss. Best rule: food first, then fill known gaps.

Nutrient	General adult reference (US, NIH ODS)	Supplement-safety point
Thiamine (B1)	About 1.1–1.2 mg/day	No established upper limit. Suspected acute deficiency or Wernicke encephalopathy is a medical emergency, not a consumer protocol.
Vitamin B12	2.4 mcg/day	No established upper limit. Dose should fit the reason (low intake vs. documented low status).
Vitamin D	600 IU/day to age 70; 800 IU/day after 70	Adult upper limit 4,000 IU/day from all sources unless a clinician is treating deficiency.
Iron	8 mg/day (men, postmenopausal women); 18 mg/day (women 19–50)	Adult upper limit 45 mg/day; do not self-prescribe without evidence of need.
Magnesium	About 310–420 mg/day from all sources	350 mg/day upper limit applies to supplements and medications, not food. High doses can cause diarrhea; caution with kidney impairment.
Calcium	About 1,000–1,200 mg/day by age and sex	Prefer food sources; count total intake from food and supplements.
Zinc	About 8 mg/day women; 11 mg/day men	Adult upper limit 40 mg/day; chronic excess can impair copper status.

General U.S. Dietary Reference Intake values from the NIH Office of Dietary Supplements; not individualized prescriptions. Country-specific values may differ.

Why this page no longer recommends a blanket stack

Earlier versions suggested 2,000–4,000 IU vitamin D, routine iron and 50–300 mg thiamine for most users. Current evidence does not support applying these doses to everyone, and the 4,000 IU figure is the unsupervised adult upper limit, not a target.

A tiered approach to the “supplement stack”

Tier	What it means
Tier 1: Food	Protein, vegetables, fruit, legumes, whole grains, nuts, seeds, dairy or fortified alternatives, seafood.
Tier 2: Basic insurance	A standard multivitamin/mineral for selected people with persistently low intake or multiple restrictions.
Tier 3: Targeted replacement	Correct documented or strongly suspected B12, vitamin D, iron, magnesium or other deficiency under clinical assessment.
Tier 4: Medical treatment	Severe deficiency, dehydration, neurologic symptoms or significant malnutrition require medical management.

Which Blood Tests Should GLP-1 Users Consider?

The 2026 ADA Standards state there are no universal recommendations for how often micronutrients should be screened; frequency should follow clinical judgment and risk. The table is a discussion list for higher-risk patients, not a standard panel.

Assessment	Why it may be useful	Who is more likely to need it
CBC	Detects anemia and other blood abnormalities.	Fatigue, restrictive diet, suspected iron/B12/folate deficiency, bleeding.
Ferritin + iron studies	Assesses iron stores and availability.	Fatigue, low intake, heavy menstrual bleeding, anemia.
Vitamin B12	Assesses B12 status.	Low animal-food intake, metformin, neurologic symptoms, prior deficiency.
25-OH vitamin D	Measures vitamin D status.	Prior deficiency, bone risk, low intake.
Magnesium	May help when GI losses or other risk exist.	Prolonged diarrhea, very low intake.
Electrolytes + kidney function	Checks for dehydration or GI losses.	Persistent vomiting or diarrhea, dizziness, low urine output.
Thiamine evaluation	Selected high-risk patients.	Severe vomiting, malnutrition, rapid loss, neurologic symptoms.
Folate / others	When diet history, CBC or symptoms suggest it.	Highly restrictive diets, anemia, malabsorption.

Do not wait for a calendar reminder

Persistent vomiting, worsening weakness, confusion or neurological symptoms need clinical assessment now, not at the next scheduled panel.

When should monitoring become more frequent?

• Very low energy intake
• Persistent nausea or vomiting; recurrent diarrhea
• Substantial or unusually rapid weight loss
• Previous nutrient deficiency; highly restrictive diet
• Malabsorptive disease or prior GI/bariatric surgery
• Older age, frailty or sarcopenia risk
• Heavy menstrual or other blood loss
• Medications affecting nutrients, such as metformin and B12

The 2026 ADA Standards identify more than 20% total weight loss or rapid loss exceeding about 4% per month as situations where micronutrient screening becomes particularly relevant.

How to Protect Nutrition During GI Side Effects

GI symptoms are usually strongest during initiation or dose escalation, so respond early rather than waiting until you are barely eating.

Nausea

• Smaller meals, eaten slowly; shorter intervals between small meals when appetite is very low.
• Temporarily reduce large or very fatty meals that worsen symptoms.
• Use nutrient-dense liquids or softer foods when solids are hard.
• Contact the prescriber if nausea is persistent or severe.

Vomiting

Repeated vomiting can cause dehydration, kidney problems, worsening nutrition and, rarely, serious thiamine deficiency. Do not push through persistent vomiting. Contact your prescribing team promptly. Seek urgent care if you cannot keep fluids down, faint, are severely weak or confused, or develop neurological symptoms.

Constipation

Combine fluids, food-based fiber, activity and, where appropriate, clinician-recommended medicines. Magnesium is sometimes used for constipation, but that does not mean every user needs a high-dose supplement; consider kidney function, interactions and diarrhea risk.

Diarrhea

Diarrhea raises fluid and electrolyte losses. Persistent or severe diarrhea, especially with dehydration, weakness or dizziness, warrants clinical evaluation.

GLP-1 Therapy, Thiamine and Wernicke Encephalopathy

Wernicke encephalopathy appears to be a rare but serious safety signal in GLP-1 users, concentrated in people with prolonged vomiting, poor intake and substantial weight loss. It does not show that routine users have widespread vitamin B1 depletion.

• A 2026 Clinical Nutrition study identified 15 cases across FDA reports, published literature and one clinical center. Most involved semaglutide or tirzepatide, and 13 of 15 had GI symptoms, weight loss, reduced appetite or malnutrition. It cannot provide an incidence rate or prove causation.
• A 2026 Obesity systematic review found six semaglutide case reports, all with prolonged GI symptoms and substantial weight loss before neurological deterioration.
• New: a 2026 British Journal of Diabetes case report describes Wernicke encephalopathy with optic neuropathy during tirzepatide therapy, and a systematic review presented at AACE 2026 reached a similar “possible safety signal” conclusion from a small number of eligible reports.

Why thiamine matters

Thiamine is required for cellular energy metabolism, including in the brain. Severe deficiency can cause Wernicke encephalopathy, a potentially life-threatening neurological syndrome.

Warning pattern

• Persistent vomiting and very poor food intake
• Rapid or substantial weight loss
• New confusion or altered mental status
• Difficulty walking or loss of coordination
• Abnormal eye movements or double vision

Possible Wernicke encephalopathy is an emergency

Go to emergency care. Do not manage suspected acute thiamine deficiency with a routine supplement schedule. Clinical thiamine treatment, usually given by injection or infusion, is time-sensitive. For clinicians: one 2026 case report notes that intravenous glucose may aggravate acute thiamine deficiency; treatment decisions belong to the treating team.

Accurate model	Unsupported simplification
GLP-1 therapy → appetite suppression and GI symptoms → reduced intake or malnutrition → higher thiamine-deficiency risk in susceptible people.	GLP-1 medication → directly drains vitamin B1 from the body.

Who Needs a More Intensive Nutrition Protocol?

Risk level	Typical features	Practical response
Lower	Adequate intake and variety, stable hydration, modest GI effects.	Food-first nutrition, protein focus, resistance training, routine follow-up.
Moderate	Low appetite, consistently small meals, restrictive diet, constipation, prior deficiency, older age or rapid loss.	Diet review, closer follow-up, targeted labs where appropriate.
High	Persistent vomiting, very low intake, major rapid loss, malabsorption, prior bariatric surgery, frailty, known deficiencies.	Prompt clinician/dietitian assessment; individualized labs and supplementation.
Emergency	Confusion, severe weakness, difficulty walking, abnormal eye movements, fainting, inability to keep fluids down.	Urgent or emergency care, not self-treatment.

Emergency symptoms

• New confusion or altered mental status
• New difficulty walking, severe loss of balance or incoordination
• Abnormal eye movements or double vision with severe nutritional compromise
• Fainting
• Severe dehydration with inability to keep fluids down
• Rapid neurological deterioration

Urgent clinical review

• Repeated vomiting
• Unable to maintain normal food or fluid intake
• Rapid or unexpectedly large weight loss
• Persistent dizziness or marked weakness
• New numbness or tingling
• Persistent diarrhea; significant constipation despite reasonable measures
• New symptoms suggesting anemia or another deficiency

The Updated GLP-1 Nutrient Protection Protocol 2026

This is a practical sequence, not a fixed supplement prescription.

Phase	Actions
1. Before or early in treatment	Record baseline diet and likely protein intake; identify restrictive diets and excluded food groups; ask about prior iron, B12 or vitamin D deficiency; review GI history and medications; set a realistic protein and meal structure; consider baseline labs when risk warrants.
2. Dose escalation	Monitor intake, hydration and GI symptoms; prioritize protein in smaller portions; watch for accidental prolonged fasting; raise persistent GI effects early with the prescriber.
3. Active weight loss	Protect protein and resistance training; maintain variety; monitor rate and size of loss; review symptoms of inadequacy; test selectively; add supplements only for a nutritional reason.
4. Very rapid loss or very low intake	Reassess total food and protein intake; review whether GI symptoms block nutrition; consider a dietitian; evaluate micronutrients by risk; treatment intensity and tolerability are the prescriber’s decision.
5. Maintenance	Continue adequate protein, nutrient-dense eating, resistance training, hydration and individualized monitoring after weight stabilizes.

10 Common GLP-1 Nutrition Mistakes

1. Eating as little as possible because appetite is gone. Lower appetite is not zero requirement.
2. Using actual body weight blindly to calculate protein. This can overestimate needs in obesity.
3. Taking iron “just in case.” Target it to demonstrated or strongly suspected deficiency.
4. Taking 2,000–4,000 IU vitamin D automatically. Needs are individual; 4,000 IU/day is the adult unsupervised upper limit.
5. Taking 50–300 mg thiamine routinely. Acute treatment and routine supplementation are different situations.
6. Replacing all food with protein shakes. Shakes fill a gap but lack the micronutrient range of varied food.
7. Ignoring constipation. It further reduces food enjoyment and intake.
8. Ignoring vomiting. It is a nutritional and hydration problem, not just a nuisance.
9. Relying only on the bathroom scale. Quality includes muscle, strength, function and adequacy.
10. Waiting for routine labs despite red flags. Concerning symptoms need evaluation when they occur.

Example Day for a GLP-1 User With Low Appetite

An example of meal structure, not an individualized diet prescription.

Time	Example	Objective
Breakfast	Greek yogurt or fortified soy yogurt, berries, chia or flax, small portion of oats	Protein, calcium, fiber, micronutrients
Lunch	Fish, chicken, tofu or tempeh with vegetables and a small serving of whole grains or legumes	Protein, iron, B vitamins, potassium, fiber
Snack	Protein shake, milk or fortified soy drink, eggs or cottage cheese if needed	Convenient protein when appetite is low
Dinner	Lean protein or legumes, cooked vegetables, whole-food carbohydrate as tolerated	Protein and micronutrient diversity
Fluids	Water and other unsweetened fluids through the day	Hydration, bowel regularity

During significant nausea, deliver the same principles through smaller, softer or liquid meals.

Clinician Protocol: What a Cardiologist Would Actually Take on a GLP-1

New, October 3, 2026. A widely shared five-item list on X.com — psyllium, a multivitamin, omega-3s “for inflammation,” vitamin D, and protein powder — drew a direct reply from Afshine Emrani, MD, FACC, a cardiologist who has prescribed semaglutide and tirzepatide. His 3 September 2026 Substack, “You’re on a GLP! What Vitamins Should You Take?”, is clinical opinion, not a trial. It is useful because it sorts that viral list by the three problems GLP-1 therapy actually creates.

This page keeps its rule: food first, then targeted replacement. Emrani’s list is added below as a conditional stack, graded against the same evidence standard used in the rest of the protocol. Where his doses sit above unsupervised limits, that is stated.

The three problems a supplement has to answer

1. You are eating less, so you absorb less of protein, B12, iron, magnesium, zinc and vitamin D. Joint-advisory data put energy-intake cuts in obesity trials at roughly 16–39%.
2. The stomach empties slowly. Anything that swells, sits, or binds can turn from helpful into harmful. This is the psyllium problem.
3. Lean mass and bone are on the clock. Depending on the study, about a quarter to nearly half of weight lost can be lean tissue if protein and resistance training are ignored. Bone density can fall with rapid loss.

A supplement that does not address one of those three is optional. A supplement that worsens one of them is a reason to stop.

How Emrani’s list maps onto this protocol

On a phone, each item opens as its own card.

Item	Emrani’s practical target	CEBM tier on this page	How to use it here
ItemProtein	Emrani’s practical target1.2–1.6 g/kg of ideal body weight, in 25–35 g servings. Protein first. Whey isolate when a full plate is impossible.	CEBM tier on this page5 (joint advisory consensus). Denominator unsettled.	How to use it hereKeep. Prefer ideal, adjusted, or fat-free mass over actual weight in obesity. Shakes fill a gap; they do not replace meals.
ItemCreatine monohydrate	Emrani’s practical target3–5 g daily. No loading. Extra water, because creatine draws water into muscle.	CEBM tier on this page2 for training populations (ISSN 2017; dose-response meta-analysis). Evidence gap on GLP-1. No published GLP-1-specific trial.	How to use it hereReasonable add-on with resistance training. It is not a substitute for protein or lifting. Expect about 1 kg extra lean mass in older-adult training trials, partly water. Skip or clear with a clinician if kidney disease is present.
ItemWater and electrolytes	Emrani’s practical target2–3 liters/day; low-sugar electrolyte on training or hot days.	CEBM tier on this page5, supported by known reduced intake and GI losses.	How to use it hereKeep, with the existing caveat: heart failure and advanced kidney disease need a different fluid target.
ItemMagnesium glycinate	Emrani’s practical target300–500 mg at night. Not oxide. Citrate short-term if constipated.	CEBM tier on this page5 for symptom use; deficiency correction is targeted.	How to use it hereForm choice is sound: oxide is poorly absorbed and mostly laxative. Conflict: the adult UL is 350 mg/day from supplements, not food. Stay at or under 350 mg unless a clinician is treating a documented low level. Diarrhea and kidney impairment are stop rules.
ItemVitamin D3 with K2	Emrani’s practical target2,000–5,000 IU D3 plus 100–200 mcg K2 with the largest meal. 25-OH D target 50–80 ng/mL. Do not start D without magnesium.	CEBM tier on this page2–3 for correcting low vitamin D. K2 for coronary calcium is early (DANCODE 2026 slowed progression; it did not reverse plaque or cut events).	How to use it hereConflict: 4,000 IU/day is the unsupervised adult UL. Use 2,000–4,000 only after a level, or under a clinician above that. K2 is optional, not core. Do not add K2 on warfarin — MK-7 can drop the INR at doses as low as about 45 mcg.
ItemVitamin B12	Emrani’s practical targetTest first. If low or low-normal, 500–1,000 mcg methylcobalamin. Higher risk with metformin, age over 60, low animal-food intake.	CEBM tier on this page3–4 for the risk pattern; dose is clinical practice.	How to use it hereMatches this page: test, do not blanket-dose. Methylcobalamin vs cyanocobalamin is a form preference, not a proven superiority in this setting.
ItemOmega-3 (EPA+DHA)	Emrani’s practical target1,000–2,000 mg combined EPA+DHA with a fatty meal, third-party tested. Reason: omega-3 index, target above 8% — not inflammation.	CEBM tier on this page2–3 for marine omega-3 and cardiovascular risk markers. Index target is proposed (Harris and von Schacky 2004), not a GLP-1 outcome.	How to use it hereKeep the correction. GLP-1 therapy already lowers hs-CRP, so “omega-3 for inflammation” is a weak reason. Low fish intake is a fair reason. Discard capsules that smell strongly fishy.
ItemPsyllium	Emrani’s practical targetNot a default. If used: 1 teaspoon, not 1 tablespoon, in a full glass of water, only if not nauseated. Separate from medicines by at least 2 hours.	CEBM tier on this page5 (pharmacologic reasoning). No GLP-1-specific trial. Bowel-obstruction risk with dry bulk fiber is on product labels.	How to use it hereAgree. Water and magnesium first for constipation. Skip if there is gastroparesis, persistent vomiting, or trouble swallowing.
ItemCoQ10 (ubiquinol)	Emrani’s practical target100–300 mg in the morning with food, only if on a statin.	CEBM tier on this page5. Statin-related CoQ10 lowering is documented; symptom benefit is inconsistent.	How to use it hereOptional, statin-only. Not part of the core GLP-1 stack.
ItemGlycine	Emrani’s practical target5 g in water at bedtime if magnesium is not enough for sleep.	CEBM tier on this page5. Small sleep-onset trials; not GLP-1-specific.	How to use it hereOptional. Not a nutrient-deficiency treatment.

What Emrani would skip — and this page agrees

• A generic multivitamin as proof you are covered. Most use magnesium oxide, folic acid, and doses too low to correct a real deficiency. A standard multi can still be reasonable insurance when intake is very low (ADA 2026, selected cases). It does not replace protein or a documented gap. A GLP-1 multivitamin trial (NCT07234916) is registered; no results yet.
• Betaine HCl and routine digestive enzymes. The problem is slow emptying, not low stomach acid. Extra acid in a stomach that holds food for hours can worsen reflux, which is already common on these drugs.
• Fat burners, thermogenics, high-dose caffeine. Appetite is already suppressed and dehydration is common. Stimulants on top of that are a palpitation risk, not a fat-loss strategy.
• Daily stimulant laxatives (senna and similar). They work, then they do not. First line remains fluid, magnesium as tolerated, movement, and a small soluble-fiber dose if nausea allows.

The two items no capsule replaces

Emrani’s close matches the joint advisory: resistance training two to three times a week is the signal that tells the body which tissue to keep. Protein and creatine supply material; lifting supplies the reason. And slower loss is better. Losing more than about 1% of body weight per week is a reason to talk to the prescriber about dose, intake, or both — not a reason to add another powder.

Labs: his panel, filtered through ADA 2026

Emrani suggests, before treatment and every 3–6 months: 25-hydroxy vitamin D (he targets 50–80 ng/mL), B12 with methylmalonic acid if borderline, ferritin and iron studies, RBC magnesium, zinc, a DEXA if available, an omega-3 index (he targets above 8%), plus ApoB, hs-CRP, fasting insulin and HbA1c.

This page does not adopt a universal 3–6 month interval. ADA Standards of Care 2026 say there is no standard micronutrient screening schedule; frequency follows risk. Use his list as a menu for higher-risk patients — very low intake, persistent vomiting or diarrhea, rapid loss, prior deficiency, metformin, vegan pattern, heavy menstrual bleeding — not as an automatic panel for every prescription.

Attribution: Afshine Ash Emrani, MD, FACC, assistant clinical professor, UCLA David Geffen School of Medicine. “You’re on a GLP! What Vitamins Should You Take?” Substack, 3 September 2026. Clinical opinion. He is not the reader’s physician; neither is this page.

AI Personalization Guide: Using This Article With Claude, ChatGPT, Gemini and Perplexity

AI assistants can help you organize questions and track patterns, but they cannot examine you, order tests or replace your prescriber. Remove names, dates of birth and ID numbers before pasting anything, and bring the output to your clinician or dietitian.

Copy-and-paste prompt template

“I take [semaglutide / tirzepatide / other] at [dose] since [month]. My typical daily intake is [foods, rough protein grams]. I have had [nausea / vomiting / constipation / none]. My weight change is [kg or % over weeks]. Diet pattern: [omnivore / vegetarian / vegan / other]. Known deficiencies or relevant medicines: [list]. Using the GLP-1 Nutrient Deficiency Protocol 2026 at glp.onedaymd.com, (1) place me in a risk tier, (2) list questions to ask my doctor or dietitian, (3) suggest which labs to ask about and why, and (4) flag any symptom that should be treated as urgent. Say clearly where the evidence is weak.”

Assistant	Good use with this article	Tip
Claude	Turn the risk tiers into a one-page question list; paste de-identified lab results and ask what each marker could mean and what to confirm with a clinician.	Ask it to separate what is established from what is uncertain, and to avoid dosing advice.
ChatGPT	Build a 3-day low-appetite meal plan around your protein target and food preferences; draft a symptom and intake log.	Ask it to cite primary sources and verify any numbers against the references below.
Gemini	Compare your current intake with the nutrient table and highlight likely gaps; organize notes alongside your own documents or calendar if you use them.	Re-check reference intakes for your country.
Perplexity	Look up the original studies listed in the references and see newer publications on Wernicke encephalopathy or micronutrient monitoring.	Open the cited papers yourself; summaries can miss study limits.

Tools and Telehealth (Affiliate Links)

Affiliate disclosure: the links in this section are affiliate links. We may earn a commission if you buy or sign up, at no extra cost to you. They are convenience options, not medical recommendations.

• Virtual care: if you need a clinician to review your symptoms, labs or GLP-1 plan, The Wellness Company virtual care is one telehealth pathway. Availability, eligibility and prescribing decisions are determined by their licensed clinicians.
• Strength training at home: resistance band sets support the resistance-training advice above.
• Portion and protein tracking: a digital kitchen scale makes it easier to estimate protein per meal.

Related reading on GLP-1 Advisor and OneDayMD:

• GLP-1 & Peptide Resource Hub (topic hub)
• GLP-1 and muscle loss: how to preserve lean mass
• GLP-1 Studies Explained: The Complete 2023–2026 Evidence Guide
• Start GLP-1 Weight Loss 2026: Compare Options, Costs & Strategy

Frequently Asked Questions

Do Ozempic, Wegovy, Mounjaro and Zepbound cause vitamin deficiencies?

They can raise the risk of nutritional inadequacy indirectly, mainly because people eat much less and may vomit or avoid food groups. Current evidence does not show that semaglutide or tirzepatide directly drain vitamins from the body. Observational data report vitamin D and iron signals, but these studies cannot prove the drug itself causes each deficiency.

What vitamins should I take with a GLP-1?

There is no universal GLP-1 vitamin stack. The best-supported approach is a nutrient-dense diet first, then targeted supplements when a deficiency is documented, intake is persistently very low, or you follow a restrictive diet. A standard-dose multivitamin can be reasonable for selected people. Ask your clinician or dietitian which gaps apply to you.

Should everyone taking a GLP-1 take thiamine (vitamin B1)?

Not necessarily. Routine high-dose thiamine is not an established requirement for every GLP-1 user. Thiamine matters most with persistent vomiting, severe food restriction, rapid weight loss or neurological symptoms. Confusion, unsteady walking or abnormal eye movements are emergencies that need hospital assessment, not a home supplement schedule.

Should I take iron on semaglutide or tirzepatide?

Not automatically. Iron needs depend on diet, menstrual blood loss, symptoms and blood tests such as ferritin and a complete blood count. Taking iron without a reason can cause side effects and, in excess, harm. Test first when you have fatigue, heavy periods, a vegetarian diet or a history of iron deficiency.

How much protein should I eat on a GLP-1?

A range of about 1.2 to 1.6 g/kg/day has been proposed during active weight loss. In obesity, using actual body weight can overestimate needs, so adjusted or reference weight, or fat-free mass, may be more appropriate. People with kidney disease, frailty or very low intake should have the target individualized by a registered dietitian.

Can GLP-1 drugs cause muscle loss?

Weight loss from any method can reduce lean mass along with fat. The amount varies with how fast you lose weight, protein intake, age and activity. Adequate protein plus progressive resistance training is the main strategy discussed in current advisories to protect muscle and physical function during treatment.

Do GLP-1 users need blood tests every 3 to 6 months?

There is no universal schedule. The 2026 ADA Standards state that no universal recommendation exists for how often to screen micronutrients. Testing should follow risk: very low intake, persistent vomiting or diarrhea, rapid or large weight loss, prior deficiency, restrictive diets, malabsorptive disease or relevant medications such as metformin.

When is GLP-1-related vomiting an emergency?

Seek urgent care if you cannot keep fluids down, feel faint, are severely weak or dehydrated, or develop confusion, difficulty walking, double vision or abnormal eye movements. Possible Wernicke encephalopathy is a medical emergency. Repeated vomiting without these signs still warrants prompt contact with your prescriber rather than pushing through.

Can a multivitamin help while on a GLP-1?

A standard-dose multivitamin/mineral can be reasonable if your intake is consistently low or you exclude major food groups. It is insurance, not a substitute for food or protein. No completed randomized trial in GLP-1 users has yet shown that routine multivitamin use improves nutrient status, although one trial is registered.

Clinical bottom line

GLP-1 therapy does not mean you need a giant supplement stack. The better model is adequate food intake, protein, dietary variety, hydration, resistance training, symptom monitoring, targeted labs and targeted supplementation when indicated.

The right response is neither complacency nor alarmism. It is nutritional surveillance proportional to risk.

Medical References and Further Reading

1. American Diabetes Association. Standards of Care in Diabetes—2026: Obesity and Weight Management for the Prevention and Treatment of Diabetes. Diabetes Care. 2026. View guideline
2. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025. DOI
3. Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026;16(1):e70070. PubMed | DOI
4. Retrospective claims analysis of nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists (461,382 adults). PubMed
5. Lev D, et al. Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: a pharmacovigilance study and literature review. Clin Nutr. 2026;57:106571. PubMed | DOI
6. Bidesie J, Oudman E. Wernicke’s Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence. Obesity. 2026. PubMed | DOI
7. Wernicke encephalopathy in patients treated with GLP-1 receptor agonists: a comprehensive systematic review. Endocr Pract 2026;32(suppl). Presented at AACE 2026. DOI
8. Wernicke’s encephalopathy following tirzepatide (case report). Br J Diabetes. 2026. DOI
9. EASO, EFAD & ECPO. Nutritional, functional, and psychological considerations for incretin-based therapies in adults. Consensus statement. 2026. PubMed
10. Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial (registered, NCT07234916). ClinicalTrials.gov
11. NIH Office of Dietary Supplements fact sheets: Thiamin | Vitamin B12 | Vitamin D | Iron | Magnesium | Calcium | Zinc

Medical disclaimer: This article is for educational and informational purposes only and is not a substitute for diagnosis, treatment or individualized medical advice. GLP-1 and dual-incretin medicines should be used under appropriate medical supervision. Nutritional needs vary with age, sex, body composition, diet, kidney and gastrointestinal health, medications, pregnancy status and other factors. Do not start, stop or change prescription medicines or high-dose supplements based solely on this article.

Where evidence is observational, case-based or pharmacovigilance-based, this page does not treat association as proof of causation. Evidence tiers follow the Oxford Centre for Evidence-Based Medicine levels and are editorial judgments.

Editorial approach: GLP-1 Advisor aims to explain emerging evidence without promoting fear, false certainty or unnecessary supplementation. Last updated October 3, 2026.